(Q33213983)

24 July 2017

1 reference

title

Etoricoxib: a highly selective COX-2 inhibitor (English)

1 reference

24 July 2017

Shaunta' D Martina

1

1 reference

24 July 2017

Kimi S Vesta

series ordinal

2

1 reference

24 July 2017

Toni L Ripley

series ordinal

3

1 reference

24 July 2017

language of work or name

English

0 references

publication date

12 April 2005

1 reference

Annals of Pharmacotherapy

24 July 2017

published in

1 reference

24 July 2017

volume

39

1 reference

24 July 2017

issue

5

1 reference

24 July 2017

page(s)

854-862

1 reference

24 July 2017

1 reference

Selective cyclooxygenase-2 inhibitors: similarities and differences

21 January 2018

1 reference

Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease.

21 January 2018

1 reference

Clinical pharmacology of novel selective COX-2 inhibitors

21 January 2018

1 reference

Why there are two cyclooxygenase isozymes

21 January 2018

1 reference

Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man.

21 January 2018

1 reference

Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers

21 January 2018

1 reference

Pharmacokinetics of Etoricoxib in Patients with Hepatic Impairment

21 January 2018

1 reference

Pharmacokinetics of etoricoxib in patients with renal impairment

21 January 2018

1 reference

Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis

21 January 2018

1 reference

Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial

21 January 2018

1 reference

Analgesic efficacy of etoricoxib in primary dysmenorrhea: results of a randomized, controlled trial

21 January 2018

1 reference

A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model

21 January 2018

1 reference

Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study

21 January 2018

1 reference

The analgesic efficacy of etoricoxib compared with oxycodone/acetaminophen in an acute postoperative pain model: a randomized, double-blind clinical trial

21 January 2018

1 reference

A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].

21 January 2018

1 reference

Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.

21 January 2018

1 reference

Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial

21 January 2018

1 reference

Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability--a randomized, placebo-controlled, 3-month trial

21 January 2018

1 reference

Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib

21 January 2018

1 reference

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events

21 January 2018

1 reference

Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials

21 January 2018

1 reference

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

21 January 2018

1 reference

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

21 January 2018

1 reference

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1E543

1 reference

24 July 2017

1 reference